Drug Database
Back to search

Poland· PL-100313925

Vipidia

A alogliptin product containing alogliptinum, registered in Poland by Takeda Pharma A/S. The same ATC class is registered in 13 of our 19 countries.

ATC A10BH04

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedVipidiaATCA10BH04REGISTER NO.PL-100313925PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about alogliptinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Alogliptin is registered in 13 of 19 countries.

Countries holding a registration under ATC A10BH04 (alogliptin), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose
Search alogliptin products by name

Alogliptin · ATC A10BH04

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of alogliptin costs, country by country.

Normalised to the WHO defined daily dose (25 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Alogliptin · price per daily dose (25 mg)

USD · FX 28 Sept 2026

  • IT Italy$4.54
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Alogliptinum
Manufacturer
Takeda Pharma A/S
Country
Poland (PL)
ATC code
A10BH04
ATC class
Alogliptin
Defined daily dose
25 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    05903263900801
  • gtin
    05903263900764

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

312 interactions on record for alogliptin.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check alogliptin against other medicinesHow interaction checks work

Alogliptin · interactions on record

312 records

  • 3 severe
  • 269 moderate
  • 40 minor

Most severe, free to view

  • GatifloxacinJ01MA16severe
  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Alogliptin in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All alogliptin products

Authorised across Europe · EMA

The same active substance is authorised in 6 EEA countries. Names it is sold under:

  • Germany · Alogliptin Heumann
  • United Kingdom (Northern Ireland) · Alogliptin Aspire Pharma, Alogliptin Torrent
  • Iceland · Vipidia
  • Liechtenstein · Vipidia
  • Malta · Alogliptin Torrent
  • Norway · Vipidia

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/73bef829-83e5-4ac8-9fe4-fdcf8b287bb8
GET /v1/drugs/73bef829-83e5-4ac8-9fe4-fdcf8b287bb8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "12,5 mg",
  "packaging": "Rp ¦ EU/1/13/844/010 ¦ 90625\n10 tabl.\n05903263900801 ¦ Rp ¦ EU/1/13/844/011 ¦ 90626\n14 tabl.\n05903263900764 ¦ Rp ¦ EU/1/13/844/012 ¦ 90627\n28 tabl.\nRp ¦ EU/1/13/844/013 ¦ 90628\n30 tabl.\nRp ¦ EU/1/13/844/014 ¦ 90629\n56 tabl.\nRp ¦ EU/1/13/844/015 ¦ 90630\n60 tabl.\nRp ¦ EU/1/13/844/016 ¦ 90631\n90 tabl.\nRp ¦ EU/1/13/844/017 ¦ 90632\n98 tabl.\nRp ¦ EU/1/13/844/018 ¦ 90633\n100 tabl.",
  "substance": "Alogliptinum 12.5 mg",
  "common_name": "Alogliptinum",
  "pl_product_id": "100313925",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about alogliptin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console